These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 26205373)

  • 1. Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation: AMADEUS Trial.
    Senoo K; Lip GY; Lane DA; Büller HR; Kotecha D
    Stroke; 2015 Sep; 46(9):2523-8. PubMed ID: 26205373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
    Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation.
    Roldán V; Vílchez JA; Manzano-Fernández S; Jover E; Gálvez J; Puche CM; Valdés M; Vicente V; Lip GY; Marín F
    Stroke; 2014 Mar; 45(3):696-701. PubMed ID: 24519407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of Age With Stroke and Death in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: AMADEUS Trial.
    Senoo K; Lip GY
    Stroke; 2015 Nov; 46(11):3202-7. PubMed ID: 26463692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Washam JB; Stevens SR; Lokhnygina Y; Halperin JL; Breithardt G; Singer DE; Mahaffey KW; Hankey GJ; Berkowitz SD; Nessel CC; Fox KA; Califf RM; Piccini JP; Patel MR;
    Lancet; 2015 Jun; 385(9985):2363-70. PubMed ID: 25749644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Body Mass Index and Adverse Outcomes in Elderly Patients With Atrial Fibrillation: The AMADEUS Trial.
    Senoo K; Lip GY
    Stroke; 2016 Feb; 47(2):523-6. PubMed ID: 26628383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of Stroke or Systemic Embolism in Paroxysmal Versus Sustained Atrial Fibrillation: The Fushimi Atrial Fibrillation Registry.
    Takabayashi K; Hamatani Y; Yamashita Y; Takagi D; Unoki T; Ishii M; Iguchi M; Masunaga N; Ogawa H; Esato M; Chun YH; Tsuji H; Wada H; Hasegawa K; Abe M; Lip GY; Akao M
    Stroke; 2015 Dec; 46(12):3354-61. PubMed ID: 26514188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial.
    Al-Khatib SM; Thomas L; Wallentin L; Lopes RD; Gersh B; Garcia D; Ezekowitz J; Alings M; Yang H; Alexander JH; Flaker G; Hanna M; Granger CB
    Eur Heart J; 2013 Aug; 34(31):2464-71. PubMed ID: 23594592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Female Sex, Time in Therapeutic Range, and Clinical Outcomes in Atrial Fibrillation Patients Taking Warfarin.
    Senoo K; Lip GY
    Stroke; 2016 Jun; 47(6):1665-8. PubMed ID: 27125527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis in patients hospitalized with permanent and nonpermanent atrial fibrillation in heart failure.
    Taillandier S; Brunet Bernard A; Lallemand B; Simeon E; Pericart L; Clementy N; Babuty D; Fauchier L
    Am J Cardiol; 2014 Apr; 113(7):1189-95. PubMed ID: 24507167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry.
    Proietti M; Laroche C; Drozd M; Vijgen J; Cozma DC; Drozdz J; Maggioni AP; Boriani G; Lip GY;
    Am Heart J; 2016 Nov; 181():83-91. PubMed ID: 27823697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project.
    Fauchier L; Lecoq C; Clementy N; Bernard A; Angoulvant D; Ivanes F; Babuty D; Lip GY
    Chest; 2016 Apr; 149(4):960-8. PubMed ID: 26425935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Alexander JH; Atar D; Gersh BJ; Hanna M; Harjola VP; Horowitz JD; Husted S; Hylek EM; Lopes RD; McMurray JJ; Granger CB;
    J Am Coll Cardiol; 2014 Jan 7-14; 63(1):52-61. PubMed ID: 24055845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study.
    Lip GYH; Lane DA; Buller H; Apostolakis S
    Chest; 2013 Dec; 144(6):1839-1847. PubMed ID: 24009027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
    Piccini JP; Stevens SR; Lokhnygina Y; Patel MR; Halperin JL; Singer DE; Hankey GJ; Hacke W; Becker RC; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Breithardt G;
    J Am Coll Cardiol; 2013 May; 61(19):1998-2006. PubMed ID: 23500298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial.
    Bahit MC; Lopes RD; Wojdyla DM; Hohnloser SH; Alexander JH; Lewis BS; Aylward PE; Verheugt FW; Keltai M; Diaz R; Hanna M; Granger CB; Wallentin L
    Int J Cardiol; 2013 Dec; 170(2):215-20. PubMed ID: 24192334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
    Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Causes of Death and Influencing Factors in Patients with Atrial Fibrillation.
    Fauchier L; Villejoubert O; Clementy N; Bernard A; Pierre B; Angoulvant D; Ivanes F; Babuty D; Lip GY
    Am J Med; 2016 Dec; 129(12):1278-1287. PubMed ID: 27476087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.